Royal Bank of Canada’s Amplify Treatments, Testing and Advancements ETF GERM Stock Holding History

Royal Bank of Canada’s Portfolio GERM Stock Details GERM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-25	Closed	–	–	7797
2024 Q1	$0	Buy	+25	New	+$465	﹤0.01%	7860
2023 Q1	–	Sell	-26	Closed	-$1K	–	7666
2022 Q4	$1K	Sell	26 -250	-91%	-$5.63K	﹤0.01%	7127
2022 Q3	$6K	Hold	276	–	–	﹤0.01%	6688
2022 Q2	$6K	Buy	276 +250	+962%	+$5.95K	﹤0.01%	6608
2022 Q1	$1K	Hold	26	–	–	﹤0.01%	7648
2021 Q4	$1K	Buy	+26	New	+$975	﹤0.01%	7574
2020 Q3	–	Sell	-385	Closed	-$11K	–	7043
2020 Q2	$11K	Buy	+385	New	+$10.4K	﹤0.01%	5810

Other funds holding GERM

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

FDCDDQ

Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

CHC

City Holding Co Charleston, West Virginia $884M AUM 27.52% 1-Year Est. Return

TAM

Tucker Asset Management Littleton, Colorado $343M AUM 17.55% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

SPIA

Steward Partners Investment Advisory New York $19.6B AUM 22.89% 1-Year Est. Return

Royal Bank of Canada's GERM Position: Q2 2024 in Review

Royal Bank of Canada sold out of Amplify Treatments, Testing and Advancements ETF (GERM) in Q2 2024, closing a stake of 25 shares.

Royal Bank of Canada first reported a position in GERM in Q2 2020 and held it in 7 quarters. The position peaked at $11K in Q2 2020. 11 funds tracked by Wall St. Rank hold GERM as of Q2 2024.

Royal Bank of Canada reported no remaining Amplify Treatments, Testing and Advancements ETF position as of Q2 2024 after selling out during the quarter.
Royal Bank of Canada sold 25 Amplify Treatments, Testing and Advancements ETF shares in Q2 2024.
Royal Bank of Canada first reported a position in Amplify Treatments, Testing and Advancements ETF in Q2 2020 and held it in 7 quarters.
Royal Bank of Canada's Amplify Treatments, Testing and Advancements ETF position peaked at $11K in Q2 2020.
11 funds tracked by Wall St. Rank held Amplify Treatments, Testing and Advancements ETF as of Q2 2024.

Based on Royal Bank of Canada's 13F filing for Q2 2024, filed 14 Aug 2024.